Dicerna Pharmaceuticals

Dicerna

Committee Composition

Banner Image
Investors & MediaCorporate GovernanceCommittee Composition

Committee Composition

Independent Director Audit Nominating and Governance Compensation
J. Kevin Buchi Independent Director Audit
Stephen Doberstein, Ph.D. Independent Director Nominating and Governance
Martin Freed, M.D. Independent Director Nominating and Governance Compensation
Patrick Gray Independent Director Audit
Stephen J. Hoffman, M.D., Ph.D. Independent Director Audit
Adam M. Koppel M.D., Ph.D. Independent Director Compensation
Marc Kozin Independent Director Compensation
Cynthia Smith Independent Director Nominating and Governance
= Independent Director = Chairperson = Member

Our mission

We interfere with disease

We use RNA interference, or RNAi, to create medicines that silence the genes that cause or contribute to disease. Our goal is to provide life-changing therapies to people living with rare and common diseases.

X
logo

Effective 28 December 2021 Dicerna Pharmaceuticals, Inc. is a wholly owned subsidiary of Novo Nordisk A/S

 

 

PRESS RELEASE
CONTINUE TO DICERNA.COM
VISIT NOVONORDISK.COM